Guided Therapeutics (GTHP) Stock Price, News & Analysis

Company Overview

Guided Therapeutics, Inc. is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S. Food and Drug Administration in 2013 and obtained CE marking for distribution within the European Union, enabling it to market its technology across multiple regions. Guided Therapeutics collaborates with academic and research institutions—including the National Cancer Institute—to validate its imaging algorithms through clinical studies conducted in both the United States and Europe. These partnerships have informed ongoing refinements to the LuViva platform and supported expansion of its distribution channels via direct sales and strategic alliances.

Founded in 1993 and headquartered in Melbourne, Florida, Guided Therapeutics leverages a multidisciplinary management team with expertise in biomedical engineering, oncology, and regulatory affairs. Building on the core technology behind LuViva, the company is exploring additional applications in gynecologic and dermatologic diagnostics. Its long-term strategy aims to extend its non‐invasive optical imaging capabilities to address a broader range of clinical needs in early disease detection.

Key Stats

• Today's Range: $0.20 to $0.22
• 50-Day Range: $0.19 to $0.39
• 52-Week Range: $0.09 to $0.54
• Volume: 22,250 shs
• Average Volume: 22,252 shs
• Market Capitalization: $19.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GTHP Stock Analysis - Frequently Asked Questions

How have GTHP shares performed this year?

Guided Therapeutics' stock was trading at $0.54 on January 1st, 2026. Since then, GTHP stock has decreased by 63.0% and is now trading at $0.20.

How were Guided Therapeutics' earnings last quarter?

Guided Therapeutics Inc. (OTCMKTS:GTHP) announced its quarterly earnings data on Monday, March, 30th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $0.59 million for the quarter.

How do I buy shares of Guided Therapeutics?

Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Guided Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Guided Therapeutics investors own include Cornerstone Strategic Investment Fund (CLM), Intel (INTC), Beam Therapeutics (BEAM), ChargePoint (CHPT), CSX (CSX), Enbridge (ENB).

Company Calendar

• Last Earnings: 3/30/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:GTHP
• CIK: 924515
• Web: www.guidedinc.com
• Phone: (770) 242-8723
• Fax: 770-242-8639
• Employees: 5
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.20 million
• Net Margins: N/A
• Pretax Margin: -416.69%
• Return on Equity: N/A
• Return on Assets: -304.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.02

Sales & Book Value

• Annual Sales: $770 thousand
• Price / Sales: 25.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.09) per share
• Price / Book: -2.22

Miscellaneous

• Outstanding Shares: 96,537,000
• Free Float: 32,021,000
• Market Cap: $19.31 million
• Optionable: Not Optionable
• Beta: 0.79